Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINIMA-2: Ranibizumab Microdoses for Diabetic Macular Edema
NCT01112085Phase 2Completed
- Sponsor
- Especialistas en Retina Médica y Quirúrgica, S.L.P.
- Start
- Apr 2010
- Primary completion
- Jan 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ranibizumab in diabetic macular edema (DME), sponsored by Especialistas en Retina Médica y Quirúrgica, S.L.P. Primary endpoint: Best Corrected Visual Acuity at 12 months. Started Apr 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01112085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01112085.